钌-106敷贴近距离放射治疗斯特奇-韦伯综合征中的弥漫性脉络膜血管瘤
Ruthenium-106 plaque brachytherapy for the treatment of diffuse choroidal hemangioma in Sturge-Weber syndrome.
作者信息
Yu Ying-Ying, Li Xiao-Xin, Liang Jian-Hong
机构信息
Department of Ophthalmology & Clinical Center of Optometry, Peking University People's Hospital, Beijing 100044, China.
Eye Diseases and Optometry Institute Peking University People's Hospital, Beijing 100044, China.
出版信息
Int J Ophthalmol. 2020 Mar 18;13(3):513-517. doi: 10.18240/ijo.2020.03.22. eCollection 2020.
AIM
To evaluate the efficacy of ruthenium-106 plaque brachytherapy for the treatment of diffuse choroidal hemangioma (DCH) in Sturge-Weber syndrome (SWS).
METHODS
A total of 8 patients with DCH in SWS managed with plaque brachytherapy were retrospectively included. Patients were treated with ruthenium-106 plaque therapy (median apex dose: 83 Gy) at the thickest tumor region. On follow-up, we recorded the tumor thickness, the best-corrected visual acuity (BCVA), subretinal fluid (SRF) status, and complications following treatment.
RESULTS
At a median follow-up of 43mo, tumor regression was observed in all cases, with a complete resolution of SRF and reduction in tumor-thickness. No radiation complications were recorded during the follow up time.
CONCLUSION
Ruthenium-106 plaque therapy to the thickest portion of the tumor seems to be a useful treatment in patients with DCH in SWS.
目的
评估106钌敷贴近距离放射治疗对斯-韦综合征（SWS）中弥漫性脉络膜血管瘤（DCH）的疗效。
方法
回顾性纳入8例接受敷贴近距离放射治疗的SWS合并DCH患者。在肿瘤最厚处采用106钌敷贴治疗（中位顶点剂量：83 Gy）。随访时，记录肿瘤厚度、最佳矫正视力（BCVA）、视网膜下液（SRF）状态及治疗后的并发症。
结果
中位随访43个月时，所有病例均观察到肿瘤消退，SRF完全消退，肿瘤厚度减小。随访期间未记录到放射性并发症。
结论
对肿瘤最厚部分进行106钌敷贴治疗似乎是SWS合并DCH患者的一种有效治疗方法。
Zotero 插件